Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 mars 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
18 mars 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and
Provide Corporate Update on Tuesday, March 26, 2024
IT Asset Disposition (ITAD) Market Size Projected to Reach USD 32,355.70 Million, Projecting 8.5% CAGR by 2032: Polaris Market Research
02 févr. 2024 08h54 HE
|
Polaris Market Research & Consulting LLP
New York, NY, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The latest research report [115+] pages with 360-degree visibility, titled “IT Asset Disposition (ITAD) Market Share, Size, Trends, Industry Analysis...
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
31 janv. 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose closes previously announced public offering and private placement
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 janv. 2024 08h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
09 déc. 2023 18h30 HE
|
Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
30 nov. 2023 16h59 HE
|
Aptose Biosciences, Inc.
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
APTO Skincare Launches in CVS
13 nov. 2023 09h43 HE
|
APTO Skincare
New retailer partnership expands the brand’s footprint and makes it even easier for busy women to grab their go-to skin care products.
Aptose Reports Results for the Third Quarter 2023
09 nov. 2023 16h00 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Third Quarter 2023
• TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
02 nov. 2023 09h00 HE
|
Aptose Biosciences, Inc.
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023